Regulus Therapeutics Inc. (RGLS)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous close | 2.2200 |
| Open | 2.2300 |
| Bid | 2.1300 x 200 |
| Ask | 2.1500 x 400 |
| Day's range | 2.0900 - 2.3100 |
| 52-week range | 1.0800 - 3.7900 |
| Volume | |
| Avg. volume | 3,110,517 |
| Market cap | 139.441M |
| Beta (5Y monthly) | 1.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5800 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.20 |
- GuruFocus.com
Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements
Financial and Clinical Progress Amidst Net Loss Wider Than Estimates
PR NewswireRegulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
ZacksBiotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
© 2024 Yahoo. All rights reserved.